Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Pfizer sues Metsera, Novo Nordisk over breach of merger deal
04:43pm, Friday, 31'st Oct 2025
Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.
Ozempic maker Novo Nordisk downgraded on governance uncertainty and strategic drift
07:33am, Friday, 31'st Oct 2025
Svenska Handelsbanken has cut Novo Nordisk (NYSE:NVO)to hold from buy and slashed its target price to DKK 330 from DKK 480, citing a breakdown in confidence over the company's direction and recent gov
Novo Nordisk CEO says job cuts affecting 9,000 staff almost complete
06:03am, Friday, 31'st Oct 2025
Novo Nordisk has notified employees impacted by the drugmaker's job cuts in the vast majority of its locations although the pace varies according to local laws, its CEO Mike Doustdar wrote in a post o
Lilly's quarterly results Thursday, combined with Novo Nordisk's unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma's hottest.
Novo: Risks Revisited And Potential Metsera Deal
05:23pm, Thursday, 30'th Oct 2025
Novo Nordisk A/S remains a Buy ahead of Q3 2025 earnings, but I reassess key risks and competitive pressures. NVO faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly,
Novo Nordisk changes tack with bold raid on Pfizer obesity deal
02:19pm, Thursday, 30'th Oct 2025
Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market unde
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
01:13pm, Thursday, 30'th Oct 2025
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
11:39am, Thursday, 30'th Oct 2025
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).
Novo Nordisk says offer for Metsera adheres to restrictions under Pfizer deal
09:52am, Thursday, 30'th Oct 2025
Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited offer for drugmaker Metsera , and that the value of its proposal far exceeded
Invesco EQV International Equity Fund Q3 2025 Performance Update
09:20am, Thursday, 30'th Oct 2025
Invesco EQV International Equity Fund's Q3 2025 performance was driven by strong returns from TSM, Legrand, Trip.com, and Shenzhen Inovance. TSM outperformed on robust AI chip demand and favorable mar
Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.
07:11am, Thursday, 30'th Oct 2025
Denmark's Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.
Pfizer Addresses Proposal for Metsera
06:57am, Thursday, 30'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a co
Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera
06:23am, Thursday, 30'th Oct 2025
Novo Nordisk said the proposal is currently subject to review by Metsera's board of directors.
Novo Nordisk gatecrashes Pfizer's takeover of obesity rival Metsera
06:06am, Thursday, 30'th Oct 2025
Novo Nordisk (NYSE:NVO) has attempted to gatecrash Pfizer Inc (NYSE:PFE, ETR:PFE)deal to buy obesity drug developer Metsera Inc (NASDAQ:MTSR), with an unsolicited offer of $6.5 billion, rising to a
Novo Nordisk makes unsolicited offer for Metsera
05:57am, Thursday, 30'th Oct 2025
Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera.
